This is a recorded version of an AACC live webinar that
was held February 26, 2015. Recently, the FDA gave 23andMe clearance to market
certain genetic carrier tests directly to consumers. This movement toward
allowing the company to offer more genetic testing services directly to
consumers brings up a number of questions. In the past, FDA ordered 23andMe to
cease marketing its Personal Genome Service because it did not feel that the
company could adequately demonstrate the test was analytically and clinically
valid. Additionally, concerns had been expressed regarding
the burden these tests may bring on an already stressed healthcare system due to
the majority of test results having limited or no clinical utility and the lack
of expert health providers to interpret and advise on DTC genetic reports.
With the regulation of laboratory-developed tests in flux,
and consumer interest in genetic testing on the rise, it's unclear what the
future holds for DTC genetic testing. Purchase this webinar and understand
what's behind the debate and what the future may look like for
direct-to-consumer genetic testing.
A Q&A session from the live webinar is also included
on the recording.